Acción PAIN THERAPEUTICS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas Pain Therapeutics, Inc. Nasdaq

Acciones

US69562K1007

Precio de cierre Nasdaq
Otros sitios de cotización
- USD - Gráfico intradía de Pain Therapeutics, Inc.
08/05 Cassava Sciences recauda más de 125 millones de dólares con la distribución de warrants MT
25/03 Cassava Sciences anuncia la finalización de la revisión provisional de seguridad de su candidato a fármaco contra el Alzheimer, el simufilam MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Cassava Sciences Raises More Than $125 Million From Warrant Distribution
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
North American Morning Briefing : Stock Futures -2-
Cassava Sciences : Warrants – Notice of Guaranteed Delivery
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
North American Morning Briefing : Investors Brace -2-
Cassava Sciences : Corporate Presentation – Second Quarter 2024
Cassava Sciences, Inc. - Redemption Date Announced for Warrants
Redemption Date Announced for Warrants
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action - SAVA
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam
Cassava Sciences : Corporate Presentation – First Quarter 2024
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción SAVA
  4. Acción
  5. Noticias Pain Therapeutics, Inc.
  6. Otros idiomas